GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...
Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...
The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...
UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...
Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks · Depemokimab is an ultra-long-acting ...
UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps ...